Open-label, Randomized Comparison of the Efficacy of Intravenous Dolasetron Mesylate and Ondansetron in the Prevention of Acute and Delayed Cisplatin-induced Emesis in Cancer Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The aim of this study is to compare the antiemetic efficacy and tolerability of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed emesis. Material and Methods: From April 2002 through October 2002, a total of 112 patients receiving cisplatin- based combination chemotherapy were randomized to receive a single i.v. dose of dolasetron 100 mg or ondansetron 8 mg, 30 minutes before the initiation of chemotherapy. In the ondansetron group, two additional doses of ondansetron 8 mg were given at intervals of 2 to 4 hours. To prevent delayed emesis, dolasetron 200 mg p.o. daily or ondansetron 8 mg p.o. bid was administered from the 2nd days to a maximum of 5 days. The primary end point was the proportion of patients that experienced no emetic episodes and required no rescue medication (complete response, CR) during the 24 hours (acute period) and during Day 2 to Day 5 2 days (delayed period), after chemotherapy. The secondary end points included the incidence and severity of emesis. Results: 105 patients were evaluable for efficacy. CR rates during the acute period were 36.0% for a single dose of dolasetron 100 mg, and 43.6% for three doses of ondansetron 8 mg. CR rates during the delayed period were 8.0% and 10.9%, respectively. There was no significant difference in the efficacy between the two groups. Adverse effects were mostly mild to moderate and not related to study medication. Conclusions: A single i.v. dose of dolasetron 100 mg is as effective as three i.v. doses of ondansetron 8 mg in preventing acute and delayed emesis after cisplatin- based chemotherapy, with a comparable safety profile.(Cancer Res Treat. 2004;36:372-376)
Abstract
Purpose: The aim of this study is to compare the antiemetic efficacy and tolerability of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed emesis. Material and Methods: From April 2002 through October 2002, a total of 112 patients receiving cisplatin- based combination chemotherapy were randomized to receive a single i.v. dose of dolasetron 100 mg or ondansetron 8 mg, 30 minutes before the initiation of chemotherapy. In the ondansetron group, two additional doses of ondansetron 8 mg were given at intervals of 2 to 4 hours. To prevent delayed emesis, dolasetron 200 mg p.o. daily or ondansetron 8 mg p.o. bid was administered from the 2nd days to a maximum of 5 days. The primary end point was the proportion of patients that experienced no emetic episodes and required no rescue medication (complete response, CR) during the 24 hours (acute period) and during Day 2 to Day 5 2 days (delayed period), after chemotherapy. The secondary end points included the incidence and severity of emesis. Results: 105 patients were evaluable for efficacy. CR rates during the acute period were 36.0% for a single dose of dolasetron 100 mg, and 43.6% for three doses of ondansetron 8 mg. CR rates during the delayed period were 8.0% and 10.9%, respectively. There was no significant difference in the efficacy between the two groups. Adverse effects were mostly mild to moderate and not related to study medication. Conclusions: A single i.v. dose of dolasetron 100 mg is as effective as three i.v. doses of ondansetron 8 mg in preventing acute and delayed emesis after cisplatin- based chemotherapy, with a comparable safety profile.(Cancer Res Treat. 2004;36:372-376)
참고문헌 (21)
- "Comparative review of 5-HT3 receptor antagonistsin the treatment of acute chemotherapy-induced nausea andvomiting", 18, pp.163~173 (2000)
- "On the receiving end--patient perception of theside-effects of cancer chemotherapy", 19, pp.203~8 (1983)
- "The impact of cytotoxic chemotherapy--perspectives from patients", pp.1~8 (1992)
- "Closing the gap in prophylactic antiemetictherapy patient factors in calculating the emetogenic potentialof chemotherapy", 3, pp.113~119 (1999)
- "A double-blind randomized study comparing intramuscular(i.m.) granisetron with i.m. granisetron plus dexamethasone inthe prevention of delayed emesis induced by cisplatin", 10, pp.465~470 (1999), TheItalian Multicenter Study Group
- "Efficacy of intravenous granisetron to control nauseaand vomiting during multiple cycles of cisplatin-based chemotherapy", 16, pp.87~93 (1998)
- "Potent 5-HT3 antagonists incorporating anovel bridged pseudopelletierine ring system", 16, pp.187~9 (1989)
- "Disposition following single- doseintravenous administration to normal male subjects", pp.693~701 (1992)
- "Characterization of the novel 5-HT3 antagonists MDL73147EF and MDL 74156 in NG108-15neuroblastoma x glioma cells", pp.9~13 (1992)
- "a potent and selective antagonist at 5-HT3 receptors", pp.87~93 (1993)
- "Pharmacokineticsof dolasetron following single- and multiple- doseintravenous administration to normal male subjects", 16, pp.177~189 (1995)
- "Dolasetron mesylate", 18, pp.506~9 (1993)
- "in cancer patientstreated with cisplatin", pp.97~102 (1994)
- "Dose-ranging evaluation of the serotonin antagonistdolasetron mesylate in patients receiving high-dosecisplatin", 12, pp.1045~9 (1994)
- "parallel study of two doses of intravenous MDL73", modia(m) (1992)
- "Dose-ranging evaluation of the antiemeticefficacy of intravenous dolasetron in patients receiving chemotherapywith doxorubicin or cyclophosphamide", 4, pp.141~146 (1996)
- "Double-blind, randomized comparison of the antiemeticefficacy of intravenous dolasetron mesylate and intravenousondansetron in the prevention of acute cisplatin-inducedemesis in patients with cancer", 14, pp.2242~2249 (1996), Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group
- "A randomized comparison of antiemetic effect of ondansetronversus MDL", pp.378~389 (1992)
- "and metoclopramideplus dexamethasone in patients receiving cisplatin", pp.108~14 (1989), Cirrincione C
- "Urinary serotonin metabolite excretion during cisplatin chemotherapy", 72, pp.2239~41 (1993)
- "5-HT3 receptor antagonists for theprevention of chemotherapy-induced nausea and vomiting", 55, pp.173~189 (1998)